Assessment of Large-Sample Unit-Dose Uniformity Tests - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Assessment of Large-Sample Unit-Dose Uniformity Tests
The authors describe the concept of the limiting discriminatory threshold (LDT) as an objective means of evaluating the inherent quality requirement of a large-sample content-uniformity test.


Pharmaceutical Technology
Volume 35, Issue 10, pp. 82-92

Discussion and conclusion

This article introduced and illustrated the LDT criterion for evaluating the performance and efficiency of large-sample UDU test proposals. The intent was not to introduce a new proposal or to provide a definitive evaluation of any specific large-sample UDU test, but merely to suggest an objective way of comparing test proposals and of ensuring that large-sample UDU tests will meet or exceed the quality standard set by the hUSP test.

The LDTs for parametric tests generally depend on the parameters of the assumed population distribution. For illustration, LDTs were examined for normal and t distributions. In principle, LDTs could be evaluated against other distributions that include skewness (e.g., log normal) or bimodality (e.g., mixed normal). The authors used 85–115% LC as the range of interest for defining coverage, although other ranges (e.g., 75–125% LC) may also be of interest. Furthermore, the LDT approach could be extended to quality measures other than coverage, or to multivariate measures.

It may not always be possible to calculate the LDT of a test directly by algebra and intuitive arguments. However, the LDT can always be obtained by extrapolation to a large sample size using simulation. This article showed how coverage corresponding to the 10% and 90% acceptance probabilities varied as a function of the sample size, which can be used to evaluate and compare the power and efficiency of competing tests.

To ensure that quality standards are maintained at an appropriate level, it is imperative that common quality criteria be identified and adopted. This article presents the LDT approach to assist in reaching this common goal.

Yanhui Hu* is principal process development engineer, and David LeBlond is senior statistician, both at Abbott Laboratories, D050Z, AMJ23, Abbott Park, IL 60064, tel. 847.938.8885,
.

*To whom all correspondence should be addressed.

Submitted: Apr. 4, 2011. Accepted: June 13, 2011.

References

1. USP 33–NF 28 Reissue, General Chapter <905>, "Uniformity of Dosage Units" (US Pharmacopeial Convention, Rockville, MD, 2010).

2. D. Sandell, et al., Drug Inf. J. 40 (3), 337–344 (2006).

3. J. Bergum and K.E. Vukovinsky, Pharm. Technol. 34 (11), 72–79 (2010).

4. M. Diener et al., Drug Inf. J. 43 (3), 287–298 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here